[
  {
    "ts": null,
    "headline": "FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS",
    "summary": "The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has passed with no clarity on when the decision will move forward again.",
    "url": "https://finnhub.io/api/news?id=5b68a6a0d1e4e6384f95ff881555072a0e5c2882dc631d987b355559b8100ded",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743709147,
      "headline": "FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS",
      "id": 133704627,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has passed with no clarity on when the decision will move forward again.",
      "url": "https://finnhub.io/api/news?id=5b68a6a0d1e4e6384f95ff881555072a0e5c2882dc631d987b355559b8100ded"
    }
  },
  {
    "ts": null,
    "headline": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
    "summary": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
    "url": "https://finnhub.io/api/news?id=f57ab0882a5b1d37612cb12eb44e395004096d9025d533fa7641bd6e86d9b6ca",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743705780,
      "headline": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
      "id": 133705356,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
      "url": "https://finnhub.io/api/news?id=f57ab0882a5b1d37612cb12eb44e395004096d9025d533fa7641bd6e86d9b6ca"
    }
  },
  {
    "ts": null,
    "headline": "​RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade)",
    "summary": "RxSight faces revenue decline and rising competition in the IOL market. Explore the impacts of economic uncertainties and why a Hold rating is suggested.",
    "url": "https://finnhub.io/api/news?id=82a3d3d456888286cbb20484ca10ef374b428a10201c646b1aa669881f554304",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743703051,
      "headline": "​RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade)",
      "id": 133700274,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1823932204/image_1823932204.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "RxSight faces revenue decline and rising competition in the IOL market. Explore the impacts of economic uncertainties and why a Hold rating is suggested.",
      "url": "https://finnhub.io/api/news?id=82a3d3d456888286cbb20484ca10ef374b428a10201c646b1aa669881f554304"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stocks Aren't in the Clear, Despite Tariff Exemption—Heard on the Street",
    "summary": "Big pharmaceutical stocks mostly rose after President Trump’s executive order exempted medicines from new tariffs. Merck, Bristol-Myers Squibb, and Johnson & Johnson were among the top performers in the S&P 500, with the sector also benefiting from its status as a defensive play.",
    "url": "https://finnhub.io/api/news?id=dafc455d6b043cbaeb717724b5933eb6ce4e53e22c177f5a35f7c74bc43607e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743690622,
      "headline": "Pharma Stocks Aren't in the Clear, Despite Tariff Exemption—Heard on the Street",
      "id": 133697704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Big pharmaceutical stocks mostly rose after President Trump’s executive order exempted medicines from new tariffs. Merck, Bristol-Myers Squibb, and Johnson & Johnson were among the top performers in the S&P 500, with the sector also benefiting from its status as a defensive play.",
      "url": "https://finnhub.io/api/news?id=dafc455d6b043cbaeb717724b5933eb6ce4e53e22c177f5a35f7c74bc43607e6"
    }
  },
  {
    "ts": null,
    "headline": "JNJ vs. PFE: Which Drug Giant is a Better Buy Now?",
    "summary": "Both JNJ & PFE expect their sales and profits to improve in 2025.",
    "url": "https://finnhub.io/api/news?id=577f8440ee8c4800f3fbc99d3e2c2f84078fbcc5869748e44935a4ea9da8042e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743688740,
      "headline": "JNJ vs. PFE: Which Drug Giant is a Better Buy Now?",
      "id": 133697705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Both JNJ & PFE expect their sales and profits to improve in 2025.",
      "url": "https://finnhub.io/api/news?id=577f8440ee8c4800f3fbc99d3e2c2f84078fbcc5869748e44935a4ea9da8042e"
    }
  },
  {
    "ts": null,
    "headline": "J&J: putting AI to work for seniors and caregivers",
    "summary": "With the world's population over 60 expected to double by 2050, the healthcare sector needs to step up specialist care for age-related conditions. At the same time, physician burnout remains a major...",
    "url": "https://finnhub.io/api/news?id=1cce23c3fb26cd863c98dbbbb86e2c259f7dfd0b3a1e800bca9ddbfba209d44b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743671785,
      "headline": "J&J: putting AI to work for seniors and caregivers",
      "id": 133696649,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "With the world's population over 60 expected to double by 2050, the healthcare sector needs to step up specialist care for age-related conditions. At the same time, physician burnout remains a major...",
      "url": "https://finnhub.io/api/news?id=1cce23c3fb26cd863c98dbbbb86e2c259f7dfd0b3a1e800bca9ddbfba209d44b"
    }
  }
]